Skip to main content

Table 2 Univariate and multivariate analysis of oncologic risk factors in patients who had received cetirizine and in those who had not received it

From: Concomitant medication of cetirizine in advanced melanoma could enhance anti-PD-1 efficacy by promoting M1 macrophages polarization

Covariate

Multivariate analysis

Univariate analysis

HR

95% CI

p-value

HR

95% CI

p-value

PFS

      

BRAF mut

1.635

0.9208 to 2.9015

0.0933

1.495

0.8725 to 2.5603

0.1434

CNS mtx

1.951

1.0940 to 3.4790

0.0235

2.159

1.3161 to 3.5423

0.0023

ECOG PS

4.859

2.2453 to 10.5135

0.0001

6.041

2.9530 to 12.3593

 < 0.0001

Gender

1.418

0.8056 to 2.4967

0.2259

1.305

0.8221 to 2.0721

0.2587

LDH

2.058

1.2155 to 3.4841

0.0072

1.635

1.0384 to 2.5740

0.0338

M category

0.95

0.7188 to 1.2554

0.7179

0.785

0.6030 to 1.0223

0.0725

Anti-H treatment

0.595

0.3596 to 0.9853

0.0436

0.545

0.3467 to 0.8566

0.0085

OS

      

BRAF mut

1.098

0.5510 to 2.1861

0.7913

1.066

0.5697 to 1.9959

0.8409

CNS mtx

1.647

0.8473 to 3.1998

0.1412

2.27

1.2923 to 3.9859

0.0043

ECOG PS

2.751

1.2144 to 6.2326

0.0153

4.487

2.2537 to 8.9347

 < 0.0001

Gender

1.943

0.9641 to 3.9145

0.0632

1.426

0.8069 to 2.5196

0.2219

LDH

2.979

1.5411 to 5.7585

0.0012

1.851

1.0747 to 3.1873

0.0264

M category

0.794

0.5298 to 1.1906

0.2646

0.634

0.4236 to 0.9483

0.0265

Anti-H treatment

0.392

0.2092 to 0.7328

0.0034

0.404

0.2340 to 0.6987

0.0012

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us